CN103860964A - Medicinal preparation for treating adult Kaschin-Beck disease - Google Patents
Medicinal preparation for treating adult Kaschin-Beck disease Download PDFInfo
- Publication number
- CN103860964A CN103860964A CN201410123529.2A CN201410123529A CN103860964A CN 103860964 A CN103860964 A CN 103860964A CN 201410123529 A CN201410123529 A CN 201410123529A CN 103860964 A CN103860964 A CN 103860964A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- caulis
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal preparation for treating adult Kaschin-Beck disease. The preparation is prepared from the following raw medicinal materials in parts by weight: 15 parts of common stelmatorypton herb, 20 parts of unpleasant swallowwort herb, 12 parts of green fig root, 10 parts of medlar, 8 parts of raw rehmannia, 9 parts of spina date seed, 5 parts of common calanthe herb, 8 parts of coix seed, 9 parts of kudzu vine root, 5 parts of rhizoma bletillae, 7 parts of honeysuckle, 6 parts of fructus aurantii, 4 parts of cactus, 3 parts of rhizoma alismatis, 2 parts of narrow-leaved lindernia, 5 parts of radix polygonati officinalis, 3 parts of fructus rosae laevigatae, 2 parts of Chinese mahonia stem, 6 parts of radix ophiopogonis, 5 parts of platycodon grandiflorum, 2 parts of tuber fleeceflower stem, 2 parts of lotus seed, 2 parts of loofah sponge, 1 part of mint, 2 parts of raspberry, 2 parts of partedleaf violet herb, 3 parts of hawthorn, 2 parts of dodder, 3 parts of cassia twig, 2 parts of oriental wormwood and 5 parts of bamboo shaving. The medicinal preparation for treating adult Kaschin-Beck disease is reasonable in formula, has the characteristics of definite curative effect, no toxic or side effect and low price, and is safe and convenient.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of adults with Kashin-Beck disease.
Background technology
Kaschin-Beck disease is a kind of endemic osteoarthritis, clinically taking articular cartilage distortion increase slightly, even necrosis is as principal character.Wherein adults with Kashin-Beck disease is because causing lopsided arthropathy in the sequela of child's Kaschin-Beck disease, and wherein to equal movable relevant joint be its main diseased region for hands, wrist, knee joint.Adults with Kashin-Beck disease has had a strong impact on the life and work of adult normal, has a strong impact on people's quality of life, therefore finds a kind of effectively medicine its treatment is had to significant meaning.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of adults with Kashin-Beck disease.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of adults with Kashin-Beck disease, it is to be made up by weight of following bulk drugs: 15 parts of Caulis Stelmatocryptonis khasiani, 20 parts of Radix Tylophorae arenicolaes (Ji Yuan is root or the aerial parts that the spirit of asclepiadaceae plant bamboo disappears), 12 parts of Radix Fici comataes, 10 parts of Fructus Lycii, 8 parts, the Radix Rehmanniae, 9 parts of Semen Ziziphi Spinosaes, a chain of 5 parts of meat, 8 parts of Semen Coiciss, 9 parts of Radix Puerariaes, 5 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 7 parts of Flos Lonicerae, 6 parts of Fructus Aurantiis, 4 parts of Radix et Caulis Opuntiae Dilleniis, 3 parts of Rhizoma Alismatis, 2 parts of Lindernia angustifolia (Benth.) Wettst.s, 5 parts of Rhizoma Polygonati Odorati, 3 parts of Fructus Rosae Laevigatae, 2 parts of Caulis Mahoniaes, 6 parts of Radix Ophiopogonis, 5 parts of Radix Platycodoniss, 2 parts of Caulis Polygoni Multiflori, 2 parts, Semen Nelumbinis, 2 parts of Retinervus Luffae Fructuss, 1 part of Herba Menthae, 2 parts of Fructus Rubies, 2 parts of Herba Violae dissectae, 3 parts of Fructus Crataegis, 2 parts of Semen Cuscutae, 3 parts of Ramulus Cinnamomi, 5 parts of 2 parts of Herba Artemisiae Scopariaes and Caulis Bambusae In Taenia.
Preferably, described medicament can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, washing liquid or decoction.
The present invention also provides the application of medicament in the medicine of preparation treatment adults with Kashin-Beck disease, it is characterized in that, described medicament is to be made up by weight of following bulk drugs: 15 parts of Caulis Stelmatocryptonis khasiani,
A chain of 5 parts of 20 parts of Radix Tylophorae arenicolaes, 12 parts of Radix Fici comataes, 10 parts of Fructus Lycii, 8 parts, the Radix Rehmanniae, 9 parts of Semen Ziziphi Spinosaes, meat, 8 parts of Semen Coiciss, 9 parts of Radix Puerariaes, 5 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 7 parts of Flos Lonicerae,
6 parts of Fructus Aurantiis, 4 parts of Radix et Caulis Opuntiae Dilleniis, 3 parts of Rhizoma Alismatis, 2 parts of Lindernia angustifolia (Benth.) Wettst.s, 5 parts of Rhizoma Polygonati Odorati, 3 parts of Fructus Rosae Laevigatae, 2 parts of Caulis Mahoniaes, 6 parts of Radix Ophiopogonis, 5 parts of Radix Platycodoniss, 2 parts of Caulis Polygoni Multiflori, 2 parts, Semen Nelumbinis,
5 parts of 2 parts of Retinervus Luffae Fructuss, 1 part of Herba Menthae, 2 parts of Fructus Rubies, 2 parts of Herba Violae dissectae, 3 parts of Fructus Crataegis, 2 parts of Semen Cuscutae, 3 parts of Ramulus Cinnamomi, 2 parts of Herba Artemisiae Scopariaes and Caulis Bambusae In Taenia.
Preferably, described medicament can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, washing liquid or decoction.
In order to understand better the present invention, with reference to " Chinese medicine voluminous dictionary " second edition (Shanghai science tech publishing house, 2005), the explanation of some crude drug that use in the present invention sees the following form:
Generally acknowledged that at present " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the most scientific the most several large advantages of the traditional Chinese medical science, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.Each medicine tight compatibility all linked with one another as arrayed troops for battle in traditional Chinese medical science prescription is its effective means that is better than Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicament according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical square tube cross too many levels, many target spots and integrate the biological mechanism regulating, can obtain than Western medicine more lastingly, therapeutic effect that more green natural has no side effect, and this curative effect is to be based upon on the accurate instruction of the original theory of above-mentioned traditional Chinese medical science tradition, the present invention is just following this principle.
For compositions of the present invention, according to the prescription compatibility theory of " monarch, minister, help, make ", Caulis Stelmatocryptonis khasiani, Radix Tylophorae arenicolae, Radix Fici comatae are monarch drug; Fructus Lycii, the Radix Rehmanniae, Semen Ziziphi Spinosae, the meat chain of rings, Semen Coicis, Radix Puerariae, Pseudobulbus Bletillae (Rhizoma Bletillae) are ministerial drug; Flos Lonicerae, Fructus Aurantii, Radix et Caulis Opuntiae Dillenii, Rhizoma Alismatis, Lindernia angustifolia (Benth.) Wettst., Rhizoma Polygonati Odorati, Fructus Rosae Laevigatae, Caulis Mahoniae, Radix Ophiopogonis, Radix Platycodonis, Caulis Polygoni Multiflori are adjuvant drug; Semen Nelumbinis, Retinervus Luffae Fructus, Herba Menthae, Fructus Rubi, Herba Violae dissectae, Fructus Crataegi, Semen Cuscutae, Ramulus Cinnamomi, Herba Artemisiae Scopariae and Caulis Bambusae In Taenia are for making medicine.All medicines are harmonious in the present invention, and reasonable recipe has determined curative effect, safe ready, has no side effect, cheap feature.
Detailed description of the invention
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for the present invention instead of limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take 15 grams of Caulis Stelmatocryptonis khasiani, 20 grams of Radix Tylophorae arenicolaes, 12 grams of Radix Fici comataes, 10 grams of Fructus Lycii, 8 grams, the Radix Rehmanniae, 9 grams of Semen Ziziphi Spinosaes, a chain of 5 grams of meat, 8 grams of Semen Coiciss, 9 grams of Radix Puerariaes, 5 grams of Pseudobulbus Bletillae (Rhizoma Bletillae), 7 grams of Flos Lonicerae, 6 grams of Fructus Aurantiis, 4 grams of Radix et Caulis Opuntiae Dilleniis, 3 grams of Rhizoma Alismatis, 2 grams of Lindernia angustifolia (Benth.) Wettst.s, 5 grams of Rhizoma Polygonati Odorati, 3 grams of Fructus Rosae Laevigatae, 2 grams of Caulis Mahoniaes, 6 grams of Radix Ophiopogonis, 5 grams of Radix Platycodoniss, 2 grams of Caulis Polygoni Multiflori, 2 grams, Semen Nelumbinis, 2 grams of Retinervus Luffae Fructuss, 1 gram of Herba Menthae, 2 grams of Fructus Rubies, 2 grams of Herba Violae dissectae, 3 grams of Fructus Crataegis, 2 grams of Semen Cuscutae, 3 grams of Ramulus Cinnamomi, 5 grams of 2 grams of Herba Artemisiae Scopariaes and Caulis Bambusae In Taenia, add 5000 milliliters, water, under the condition of 90 DEG C of backflows, heat 5 hours.Filter, filtrate is decoction of the present invention.
Experimental example
Physical data
Choose my institute from January, 2012 to 2,013 90 routine patients that year December receives as object of study, be diagnosed as the large patient with bone disease of adult according to China's Diagnostic Criteria of Kashin Beck Disease, get rid of the immune diseases such as rheumatoid arthritis simultaneously.This research and utilization statistics software is divided into treatment group and matched group by all patients by Therapeutic Method difference, each 45 examples.Wherein treatment group man 32 examples, female's 13 examples, age 42-72 year, average (51.2 ± 3.3) year, matched group man 29 examples, female's 16 examples, age 41-71 year, average (51.5 ± 2.9) year.Two groups of patients sex, age and etc. aspect not statistically significant (P>0.05), there is comparability.
The oral anti-hyperosteogeny tablets of matched group patient is treated (purchased from Foshan Luo pioneer's pharmacy pharmaceutcal corporation, Ltd).Carry out 3 times/day, each 3,20d is 1 course for the treatment of, treats continuously 3 courses for the treatment of.
Treatment group is treated with the decoction of preparing in embodiment, once a day, and each oral 100 milliliters.20d is 1 course for the treatment of, treats continuously 3 courses for the treatment of.
Observe and evaluation methodology
The present invention is on the basis of the Kaschin-Beck disease therapeutic effect criterion up-to-date according to China; the clinical efficacy of medicine is divided into 4 classes by the performance that finishes rear patient the course for the treatment of: recovery from illness: arthralgia disappears; function of joint is clearly better; it is normal that work capacity is recovered, can be successfully completed put the palms together before one, hands touches shoulder, the test of squatting down; Effective: arthralgia disappears substantially, joint merit major part has clear improvement, work capacity normal, can put the palms together before one, hands touch shoulder, the test of squatting down, therapeutic effect of syndrome index >60%; Effective: arthralgia alleviates, function of joint part is improved, but palm has stretched obstacle completely, puts the palms together before one, hands touches shoulder, the test effect of squatting down is not good, therapeutic effect of syndrome index >30%; Invalid: symptom without being clearly better, therapeutic effect of syndrome index <30%.It is considered herein that treatment recovery from illness, effective and effectively all can think that medicine is totally effective.
Statistical method
The present invention adopts SPSS14.0 software to carry out t inspection to data, has statistical significance in the time of P<0.05.
Result
The comparison of the indices closing with bone photo before and after treatment
This research is marked to two groups of patient's indices relevant with osteoarthrosis before treatment, finds the score value not statistically significant (P>0.05) of two groups, has good comparability.After finishing the course for the treatment of, score value two groups of patients of inferior comparison is found, the recovery for the treatment of group patient Leguesne scoring, erythrocyte sedimentation rate, CRP, locomotor activity, swelling is all obviously better than matched group, and two component values have statistical significance (P<0.05).As shown in table 1.
Clinical total effective rate comparison
Clinical data statistics is shown, the clinical total effective rate for the treatment of group up to 97.8% far away higher than
66.7% clinical total effective rate of matched group.And two groups of differences have statistical significance (P<0.05).
In table 2.
| Group | Number of cases | Recovery from illness | Effective | Effectively | Invalid | Total effective rate (%) |
| Treatment group | 45 | 15 | 14 | 15 | 1 | 97.8 |
| Matched group | 45 | 0 | 10 | 20 | 15 | 66.7 |
Claims (4)
1. treat the medicament of adults with Kashin-Beck disease for one kind, it is characterized in that, it is to be made up by weight of following bulk drugs: 15 parts of Caulis Stelmatocryptonis khasiani, 20 parts of Radix Tylophorae arenicolaes, 12 parts of Radix Fici comataes, 10 parts of Fructus Lycii, 8 parts, the Radix Rehmanniae, 9 parts of Semen Ziziphi Spinosaes, a chain of 5 parts of meat, 8 parts of Semen Coiciss, 9 parts of Radix Puerariaes, 5 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 7 parts of Flos Lonicerae, 6 parts of Fructus Aurantiis, 4 parts of Radix et Caulis Opuntiae Dilleniis, 3 parts of Rhizoma Alismatis, 2 parts of Lindernia angustifolia (Benth.) Wettst.s, 5 parts of Rhizoma Polygonati Odorati, 3 parts of Fructus Rosae Laevigatae, 2 parts of Caulis Mahoniaes, 6 parts of Radix Ophiopogonis, 5 parts of Radix Platycodoniss, 2 parts of Caulis Polygoni Multiflori, 2 parts, Semen Nelumbinis, 2 parts of Retinervus Luffae Fructuss, 1 part of Herba Menthae, 2 parts of Fructus Rubies, 2 parts of Herba Violae dissectae, 3 parts of Fructus Crataegis, 2 parts of Semen Cuscutae, 3 parts of Ramulus Cinnamomi, 5 parts of 2 parts of Herba Artemisiae Scopariaes and Caulis Bambusae In Taenia.
2. the medicament for the treatment of adults with Kashin-Beck disease according to claim 1, is characterized in that, described medicament can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, washing liquid or decoction.
3. the application of medicament in the medicine of preparation treatment adults with Kashin-Beck disease, it is characterized in that, described medicament is to be made up by weight of following bulk drugs: 15 parts of Caulis Stelmatocryptonis khasiani, 20 parts of Radix Tylophorae arenicolaes, 12 parts of Radix Fici comataes, 10 parts of Fructus Lycii, 8 parts, the Radix Rehmanniae, 9 parts of Semen Ziziphi Spinosaes, a chain of 5 parts of meat, 8 parts of Semen Coiciss, 9 parts of Radix Puerariaes, 5 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 7 parts of Flos Lonicerae, 6 parts of Fructus Aurantiis, 4 parts of Radix et Caulis Opuntiae Dilleniis, 3 parts of Rhizoma Alismatis, 2 parts of Lindernia angustifolia (Benth.) Wettst.s, 5 parts of Rhizoma Polygonati Odorati, 3 parts of Fructus Rosae Laevigatae, 2 parts of Caulis Mahoniaes, 6 parts of Radix Ophiopogonis, 5 parts of Radix Platycodoniss, 2 parts of Caulis Polygoni Multiflori, 2 parts, Semen Nelumbinis, 2 parts of Retinervus Luffae Fructuss, 1 part of Herba Menthae, 2 parts of Fructus Rubies, 2 parts of Herba Violae dissectae, 3 parts of Fructus Crataegis, 2 parts of Semen Cuscutae, 3 parts of Ramulus Cinnamomi, 5 parts of 2 parts of Herba Artemisiae Scopariaes and Caulis Bambusae In Taenia.
4. application according to claim 3, is characterized in that, described medicament can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, washing liquid or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410123529.2A CN103860964B (en) | 2014-03-28 | 2014-03-28 | A kind of medicament for the treatment of adults with Kashin-Beck disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410123529.2A CN103860964B (en) | 2014-03-28 | 2014-03-28 | A kind of medicament for the treatment of adults with Kashin-Beck disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103860964A true CN103860964A (en) | 2014-06-18 |
| CN103860964B CN103860964B (en) | 2016-03-16 |
Family
ID=50900351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410123529.2A Expired - Fee Related CN103860964B (en) | 2014-03-28 | 2014-03-28 | A kind of medicament for the treatment of adults with Kashin-Beck disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103860964B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434880A (en) * | 2015-12-29 | 2016-03-30 | 李同生 | Traditional Chinese medicine preparation for treating Kaschin-Beck disease and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340345A (en) * | 2000-08-30 | 2002-03-20 | 孙绍波 | Orally-applied medicine for treating hyperosteogeny |
| CN101152446A (en) * | 2007-09-19 | 2008-04-02 | 曾玉华 | Medical ointment for treating hyperosteogeny |
-
2014
- 2014-03-28 CN CN201410123529.2A patent/CN103860964B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340345A (en) * | 2000-08-30 | 2002-03-20 | 孙绍波 | Orally-applied medicine for treating hyperosteogeny |
| CN101152446A (en) * | 2007-09-19 | 2008-04-02 | 曾玉华 | Medical ointment for treating hyperosteogeny |
Non-Patent Citations (2)
| Title |
|---|
| 张红参等: "大骨节Ⅱ号方治疗肝肾亏虚气滞血瘀型大骨节病的临床观察", 《广西中医药》, vol. 34, no. 2, 30 April 2011 (2011-04-30), pages 8 - 11 * |
| 赵惠民等: "中药熏洗配合仙灵骨葆胶囊治疗成人大骨节病临床观察", 《医学理论与实践》, vol. 25, no. 2, 31 January 2012 (2012-01-31), pages 177 - 178 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434880A (en) * | 2015-12-29 | 2016-03-30 | 李同生 | Traditional Chinese medicine preparation for treating Kaschin-Beck disease and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103860964B (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432545B (en) | A kind of medicine for pediatrics febricide and preparation method thereof | |
| CN100478017C (en) | Cathartic medicine composition | |
| CN101670011A (en) | Medicament for treating rheumatism and rheumatoid and preparation method thereof | |
| CN100348235C (en) | Traditional Chinese medicine preparation for treating infantile diarrhea and preparation method thereof | |
| CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN103860964B (en) | A kind of medicament for the treatment of adults with Kashin-Beck disease | |
| CN103520692A (en) | Preparation method for medicament for treating infantile suppurative tonsillitis | |
| CN104435125A (en) | Traditional Chinese medicine composition preparation for treating viral hepatitis | |
| CN104888137A (en) | Medicinal preparation for treatment of polycystic ovarian syndrome | |
| CN104225387A (en) | Traditional Chinese medicine composition for treating damp-heat blocked type diabetes feet | |
| CN103721109A (en) | Medicament for treating chronic cholecystitis | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN103623242B (en) | Medicament for treating hyperlipemia on inspection | |
| CN103349767B (en) | Inula nervosa Wall oil capsule preparation and preparation method thereof | |
| CN103830684B (en) | One treats menorrheal pharmaceutical composition and application thereof | |
| CN103099861B (en) | Six rattans are drunk in treatment rheumatoid arthritis | |
| CN106692645A (en) | Traditional Chinese medicine for treating lymphatic tuberculosis, and preparation method thereof | |
| CN104435676A (en) | Chinese medicinal composition for treating rheumatic arthralgia as well as preparation method and application thereof | |
| CN104857489A (en) | Medicinal preparation for curing periarthritis of shoulder | |
| CN103610906A (en) | Pharmaceutical composition for treating pain from rheumatism | |
| CN114588242A (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN104825651A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia | |
| CN103860975A (en) | Traditional Chinese medicine for treating psoriasis | |
| CN108578611A (en) | Treat the compound Chinese medicinal preparation and preparation method thereof of gout | |
| CN105267419A (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 Termination date: 20170328 |